SMG7 and neoplasm: Analysis of the PTC+-luciferase on day 7 showed that both the tumor (EtOH 1.000% ± 0.1590 & 4-OHT 3.475% ± 0.3038; P = 0.0022) and clone 5 (EtOH 1.000% ± 0.1023 & 4-OHT 2.591% ± 0.2262; P = 0.0463) cells presented a ~ threefold significant increase in the PTC+-containing luciferase, indicating that SMG7 is required for full NMD activity in our RMS cells (see Fig. 3b,c).